LISTING OF THE CLAIMS:

1. (Currently Amended) A compound of formula (I):



Wherein A is an aromatic moiety or selected from benzyl, C_1-C_{16} alkyl, dialkylamino, dialkylaminoalkyl, alkoxyalkyl, cyano, and mono-, di-, or tri-hydroxyalkyl and/or aryl,

B is an aromatic moiety,

R_1 and R_2 are independently C_1 to C_6 alkyl or NR_1R_2 forms a 5 to 8 membered ring optionally containing one or two additional heteroatoms selected from nitrogen, oxygen and sulphur and which is optionally substituted by C_1 to C_6 alkyl, and

n is 0 or 1,

and salts and hydrates thereof.

2. (Currently Amended) ~~A~~ The ~~as claimed in~~ compound of claim 1, wherein the moiety NR_1R_2 is 4-methylpiperidinyl.

3. (Currently Amended) ~~A~~ The compound ~~as claimed in~~ of claim 1 ~~or 2~~, wherein A is an aromatic moiety, and A and B are independently selected from phenyl, naphthyl, azobenzene, or a 5 or 6 membered heteroaryl ring or a benzofused heteroaryl ring containing from 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur, any of which may be optionally substituted with one or more of C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, halo, cyano, nitro, C_{1-6} alkylcarbonyl, and trifluoromethyl.

4. (Currently Amended) ~~A~~ The compound ~~as claimed in any preceding~~ of claim 1, wherein A is phenyl, benzyl, naphth-1-yl or pyridin-2-yl.

5. (Currently Amended) ~~A~~ The compound ~~as claimed in any preceding~~ of claim 1, wherein A has one or more of the following substituents: cyano, methoxy, acetyl, nitro ~~and~~ or methyl.

6. (Currently Amended) ~~A~~ The compound ~~a claimed in~~ of claim ~~4 or 5~~ 1 wherein A is monosubstituted phenyl.

7. (Currently Amended) ~~A~~ The compound ~~as claimed in any one~~ of ~~claims~~ claim 1 ~~to 5~~, wherein A is p-toluidine, m-anisidine or naphth-1-yl.

8. (Currently Amended) ~~A~~ The compound ~~as claimed in any preceding~~ of claim 1, wherein B is phenyl, naphth-1-yl or thiophen-2-yl.

9. (Currently Amended) ~~A~~ The compound ~~as claimed in any preceding~~ of claim 1, wherein B has one or more of the following substituents: methyl, methoxy, nitro, bromo, trifluoromethyl, acetamido ~~and~~ or phenyl.

10. (Currently Amended) ~~A~~ The compound ~~as claimed in any preceding~~ of claim 1, wherein B is mono-or di-substitued phenyl.

11. (Currently Amended) ~~A~~ The compound ~~as claimed in any one~~ of ~~claims~~ claim 1 ~~to 9~~, wherein B is m-toluidine, naphth-1-yl, m-nitrophenyl, 4-biphenyl or m,p-dimethoxyphenyl.

12. (Currently Amended) ~~A~~ The compound ~~as claimed in any preceding~~ of claim 1, wherein n is 1 and B is phenyl.

13. (Currently Amended) ~~A~~ The compound ~~as claimed in any~~ of ~~claims~~ claim 1 ~~to 11~~, wherein n is 0.

14. (Currently Amended) A compound as ~~claimed~~ in claim 1, having one of the following formulae:







15. (Currently Amended) ~~A~~ The compound ~~as claimed in any preceding~~ of claim 1 which has (R) stereochemistry at C*.

16. (Currently Amended) A compound which is ~~metabolised~~ metabolized or otherwise converted in vivo to a compound claimed in ~~any one of claims~~ claim 1 ~~to 15~~.

17. (Currently Amended) A method of ~~synthesising~~ synthesizing a compound of ~~any one of claims~~ claim 1 ~~to 15~~ comprising ~~the steps of~~

(i) coupling a compound of formula (II) with a compound of formula (III) or coupling a compound of formula (IV) with a compound of formula (V),





~~Compound~~ (II) ~~Compound~~ (III)





~~Compound~~ (IV) ~~Compound~~ (V)

~~where~~ wherein L is a leaving group and A, B and n are as defined in formula (I),

(ii) removing any protecting groups which may be present and

(iii) optionally forming a pharmaceutically acceptable salt.

18. (Currently Amended) ~~A compound as claimed in~~ The method of claim 17, wherein L is halogen.

19. (Currently Amended) ~~A compound as claimed in~~ The method of claim 17 ~~or 18~~, wherein compounds of formulae (II) and (III) are coupled and L is chloro.

20. (Currently Amended) ~~A compound as claimed in~~ The method of claim 17 ~~or 18~~, wherein compounds of formula (IV) and (V) are coupled and L is iodo.

21. (Currently Amended) The use of a compound ~~as claimed in any one~~ of ~~claims~~ claim 1 ~~to 15~~ as a 5-HT7 receptor ligand and/or as a 5-HT7 receptor antagonist.

22. (Currently Amended) The use ~~as claimed in~~ of claim 21, wherein said compound exhibits selectivity towards the 5-HT7 receptor over one or more other 5-HT receptor subtypes.

23. (Currently Amended) A method of treatment of a mammal afflicted with a CNS disorder, or prophylaxis in a mammal at risk of such a CNS disorder, by administration of a therapeutically effective amount of a compound ~~as claimed of the claims~~ claim 1 ~~to 15~~.

24. (Currently Amended) A pharmaceutical formulation comprising a compound ~~as claimed in any one of claims~~ claim 1 ~~to 16~~ in admixture with a pharmaceutically acceptable carrier therefor.

25. (Currently Amended) The use of a compound as claimed in ~~any one of claims~~ claim 1 ~~to 16~~ in the preparation of a medicament, for the treatment or prophylaxis of a CNS disorder, inflammation, spastic colon, renal disorders, hypotension, cardiovascular shock, stroke, septic shock or gastrointestinal conditions such as irritable bowel syndrome.